eXoZymes lasse.g@exozymes.com https://exozymes.twentythree.com en-us Visualplatform http://blogs.law.harvard.edu/tech/rss eXoZymes episodic no https://exozymes.twentythree.com/files/rv0.0/sitelogo.gif https://exozymes.twentythree.com http://exozymes.twentythree.com/interview-cayman-chemical-validates <p><p>Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently. During the run, the team encountered real-world conditions - including pH variation and precipitation - which often cause enzyme-based processes to fail. Despite this, the reaction continued to perform reliably and delivered strong results, ultimately producing more than 500 grams of pharma-grade N-<em>trans</em>-caffeoyltyramine (NCT) at 99.6% purity, a result that is difficult to obtain in biomanufacturing without extensive purification steps. Additionally, the 99% conversion of feedstock to end product highlights a level of efficiency that is challenging to achieve and maintain in traditional biomanufacturing.</p><p></p><p>For Cayman Chemical, the outcome stood out based on prior experience as highlighted by Patrick Westcott, Director of Catalog Chemistry Production at Cayman Chemical: “<em>I’ve performed a lot of cell-based enzymatic biocatalysis over the years; it is a critical component of what we do at Cayman. One common aspect of this work is a drop in efficacy during scale-up. Anytime you move up in scale orders of magnitude, a process changes enough that it is considered a different process altogether.”</em></p><p></p><p>Westcott, continues, <em>“During the experiment, from the first sample that we took the analysis showed over a 99% conversion rate. There was some concern because I thought that that maybe was a little bit too high. So, we decided to take a second sample to see if it maintained a similar conversion rate. And we were a little surprised to find out that we actually did achieve this 99% conversion in our first 100-fold scale up of their process. That was very much an aha moment for us!</em>”</p></p><p><a href="http://exozymes.twentythree.com/interview-cayman-chemical-validates"><img src="http://exozymes.twentythree.com/64968575/122969142/d406da6a433f2b61ac7a70d1464afefe/standard/download-39-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/122969142 Wed, 18 Mar 2026 13:59:35 GMT Interview: Cayman Chemical validates eXoZymes' technology and scalability Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently. During the run, the team encountered real-world conditions - including pH variation and precipitation - which often cause enzyme-based processes to fail. Despite this, the reaction continued to perform reliably and delivered strong results, ultimately producing more than 500 grams of pharma-grade N-trans-caffeoyltyramine (NCT) at 99.6% purity, a result that is difficult to obtain in biomanufacturing without extensive purification steps. Additionally, the 99% conversion of feedstock to end product highlights a level of efficiency that is challenging to achieve and maintain in traditional biomanufacturing.For Cayman Chemical, the outcome stood out based on prior experience as highlighted by Patrick Westcott, Director of Catalog Chemistry Production at Cayman Chemical: “I’ve performed a lot of cell-based enzymatic biocatalysis over the years; it is a critical component of what we do at Cayman. One common aspect of this work is a drop in efficacy during scale-up. Anytime you move up in scale orders of magnitude, a process changes enough that it is considered a different process altogether.”Westcott, continues, “During the experiment, from the first sample that we took the analysis showed over a 99% conversion rate. There was some concern because I thought that that maybe was a little bit too high. So, we decided to take a second sample to see if it maintained a similar conversion rate. And we were a little surprised to find out that we actually did achieve this 99% conversion in our first 100-fold scale up of their process. That was very much an aha moment for us!” Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently. During the run, the team encountered... eXoZymes 08:01 <p><p>Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently. During the run, the team encountered real-world conditions - including pH variation and precipitation - which often cause enzyme-based processes to fail. Despite this, the reaction continued to perform reliably and delivered strong results, ultimately producing more than 500 grams of pharma-grade N-<em>trans</em>-caffeoyltyramine (NCT) at 99.6% purity, a result that is difficult to obtain in biomanufacturing without extensive purification steps. Additionally, the 99% conversion of feedstock to end product highlights a level of efficiency that is challenging to achieve and maintain in traditional biomanufacturing.</p><p></p><p>For Cayman Chemical, the outcome stood out based on prior experience as highlighted by Patrick Westcott, Director of Catalog Chemistry Production at Cayman Chemical: “<em>I’ve performed a lot of cell-based enzymatic biocatalysis over the years; it is a critical component of what we do at Cayman. One common aspect of this work is a drop in efficacy during scale-up. Anytime you move up in scale orders of magnitude, a process changes enough that it is considered a different process altogether.”</em></p><p></p><p>Westcott, continues, <em>“During the experiment, from the first sample that we took the analysis showed over a 99% conversion rate. There was some concern because I thought that that maybe was a little bit too high. So, we decided to take a second sample to see if it maintained a similar conversion rate. And we were a little surprised to find out that we actually did achieve this 99% conversion in our first 100-fold scale up of their process. That was very much an aha moment for us!</em>”</p></p><p><a href="http://exozymes.twentythree.com/interview-cayman-chemical-validates"><img src="http://exozymes.twentythree.com/64968575/122969142/d406da6a433f2b61ac7a70d1464afefe/standard/download-39-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/chief-scientific-officer-tyler <p></p><p><a href="http://exozymes.twentythree.com/chief-scientific-officer-tyler"><img src="http://exozymes.twentythree.com/64968567/118431611/a83a90707933e3036dfa9faf3b600fc7/standard/download-18-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/118431611 Fri, 14 Nov 2025 00:11:36 GMT Chief Scientific Officer, Tyler Korman, PhD eXoZymes 03:42 <p></p><p><a href="http://exozymes.twentythree.com/chief-scientific-officer-tyler"><img src="http://exozymes.twentythree.com/64968567/118431611/a83a90707933e3036dfa9faf3b600fc7/standard/download-18-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/how-exozymes-uses-ai-tyler-korman <p></p><p><a href="http://exozymes.twentythree.com/how-exozymes-uses-ai-tyler-korman"><img src="http://exozymes.twentythree.com/64968571/118427054/5e66353b3a92d60027c2d8a108e00210/standard/download-14-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/118427054 Tue, 11 Nov 2025 19:17:13 GMT How eXoZymes uses AI - Tyler Korman (part 1) eXoZymes 05:16 <p></p><p><a href="http://exozymes.twentythree.com/how-exozymes-uses-ai-tyler-korman"><img src="http://exozymes.twentythree.com/64968571/118427054/5e66353b3a92d60027c2d8a108e00210/standard/download-14-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/exozymes-launches-subsidiary-nctx <p><p>At the yearly SynBioBeta conference, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced the formation of <em>‘NCTx, LLC’</em> (NCTx), a purpose-built subsidiary company focused on the development and production of N-trans-caffeoyltyramine - a very rare, plant-derived compound with emerging relevance in the areas of metabolic health, gut integrity, and liver function.</p><p></p><p>Full story here:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/nctx-launch">https://exozymes.com/blog/nctx-launch</a></p></p><p><a href="http://exozymes.twentythree.com/exozymes-launches-subsidiary-nctx"><img src="http://exozymes.twentythree.com/64968580/112378102/1bd1b7fcaf04c5f612c07d24da9270db/standard/download-21-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/112378102 Tue, 06 May 2025 22:18:50 GMT eXoZymes launches subsidiary, NCTx, to unlock a promising compound for gut... At the yearly SynBioBeta conference, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced the formation of ‘NCTx, LLC’ (NCTx), a purpose-built subsidiary company focused on the development and production of N-trans-caffeoyltyramine - a very rare, plant-derived compound with emerging relevance in the areas of metabolic health, gut integrity, and liver function.Full story here:https://exozymes.com/blog/nctx-launch At the yearly SynBioBeta conference, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced the formation of... eXoZymes 03:19 <p><p>At the yearly SynBioBeta conference, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced the formation of <em>‘NCTx, LLC’</em> (NCTx), a purpose-built subsidiary company focused on the development and production of N-trans-caffeoyltyramine - a very rare, plant-derived compound with emerging relevance in the areas of metabolic health, gut integrity, and liver function.</p><p></p><p>Full story here:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/nctx-launch">https://exozymes.com/blog/nctx-launch</a></p></p><p><a href="http://exozymes.twentythree.com/exozymes-launches-subsidiary-nctx"><img src="http://exozymes.twentythree.com/64968580/112378102/1bd1b7fcaf04c5f612c07d24da9270db/standard/download-21-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/ai-transforming-biotechnology-from <p><p>Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states:</p><p></p><p>"The Large Language Models (LLMs) actually got to learn our vocabulary by breaking down the English language to its core constituents - the 26 letters of the alphabet. Then the LLM identifies patterns and stitches the letters together in order to coherently answer the questions we give it. Conversely, you can think of enzymes in the same way. Enzymes are made up of 20 amino acids and LLMs can make the same correlations between these amino acids to get to stable structures. We can use these stable structures to make better enzymes and even select for properties that would up-classify them to exozymes."</p><p></p><p>Full story:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/alphafold-to-exozymes">https://exozymes.com/blog/alphafold-to-exozymes</a></p><p>#enzymes #exozymes #biomade #alphafold #proteinstructure&nbsp;</p></p><p><a href="http://exozymes.twentythree.com/ai-transforming-biotechnology-from"><img src="http://exozymes.twentythree.com/64968568/112222080/907d40ec2fa6184b4e8499629bfb2e3e/standard/download-21-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/112222080 Mon, 28 Apr 2025 20:47:39 GMT AI transforming biotechnology: From form with AlphaFold to function with... Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states:"The Large Language Models (LLMs) actually got to learn our vocabulary by breaking down the English language to its core constituents - the 26 letters of the alphabet. Then the LLM identifies patterns and stitches the letters together in order to coherently answer the questions we give it. Conversely, you can think of enzymes in the same way. Enzymes are made up of 20 amino acids and LLMs can make the same correlations between these amino acids to get to stable structures. We can use these stable structures to make better enzymes and even select for properties that would up-classify them to exozymes."Full story:https://exozymes.com/blog/alphafold-to-exozymes#enzymes #exozymes #biomade #alphafold #proteinstructure Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states:"The Large Language Models (LLMs) actually got to learn our vocabulary by breaking down the English language to its core constituents - the 26 letters of the alphabet. Then... eXoZymes 04:04 <p><p>Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states:</p><p></p><p>"The Large Language Models (LLMs) actually got to learn our vocabulary by breaking down the English language to its core constituents - the 26 letters of the alphabet. Then the LLM identifies patterns and stitches the letters together in order to coherently answer the questions we give it. Conversely, you can think of enzymes in the same way. Enzymes are made up of 20 amino acids and LLMs can make the same correlations between these amino acids to get to stable structures. We can use these stable structures to make better enzymes and even select for properties that would up-classify them to exozymes."</p><p></p><p>Full story:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/alphafold-to-exozymes">https://exozymes.com/blog/alphafold-to-exozymes</a></p><p>#enzymes #exozymes #biomade #alphafold #proteinstructure&nbsp;</p></p><p><a href="http://exozymes.twentythree.com/ai-transforming-biotechnology-from"><img src="http://exozymes.twentythree.com/64968568/112222080/907d40ec2fa6184b4e8499629bfb2e3e/standard/download-21-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/gen-biotechnology-exozymes-as-the <p></p><p><a href="http://exozymes.twentythree.com/gen-biotechnology-exozymes-as-the"><img src="http://exozymes.twentythree.com/64968579/111961083/8738b1a8767c1675f423c7675e649e87/standard/download-19-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/111961083 Mon, 21 Apr 2025 20:54:59 GMT GEN Biotechnology: exozymes as the cover story in April 2025 issue eXoZymes 01:14 <p></p><p><a href="http://exozymes.twentythree.com/gen-biotechnology-exozymes-as-the"><img src="http://exozymes.twentythree.com/64968579/111961083/8738b1a8767c1675f423c7675e649e87/standard/download-19-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/bloomberg-tv-interview-with-tyler-1 <p></p><p><a href="http://exozymes.twentythree.com/bloomberg-tv-interview-with-tyler-1"><img src="http://exozymes.twentythree.com/64968578/111817046/b2ef30ed519c94858379ec8c6ac92b91/standard/download-18-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/111817046 Tue, 15 Apr 2025 15:14:57 GMT Bloomberg TV interview with Tyler Korman, co-founder and VP of Research eXoZymes 06:09 <p></p><p><a href="http://exozymes.twentythree.com/bloomberg-tv-interview-with-tyler-1"><img src="http://exozymes.twentythree.com/64968578/111817046/b2ef30ed519c94858379ec8c6ac92b91/standard/download-18-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/bioclick-an-enzyme-engineering <p><p>BioClick: Exponentially increasing the rate of data acquisition by coupling AI with enzyme engineering and high-throughput screening – that unlocks the automated design of novel small molecules.</p><p></p><p>Read more:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/bioclick">https://exozymes.com/blog/bioclick</a></p></p><p><a href="http://exozymes.twentythree.com/bioclick-an-enzyme-engineering"><img src="http://exozymes.twentythree.com/64968579/111817348/bf0447a271960bbe9b934c5daa4bd1eb/standard/download-18-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/111817348 Thu, 10 Apr 2025 22:13:58 GMT BioClick - an enzyme engineering game-changer BioClick: Exponentially increasing the rate of data acquisition by coupling AI with enzyme engineering and high-throughput screening – that unlocks the automated design of novel small molecules.Read more:https://exozymes.com/blog/bioclick BioClick: Exponentially increasing the rate of data acquisition by coupling AI with enzyme engineering and high-throughput screening – that unlocks the automated design of novel small molecules.Read more:https://exozymes.com/blog/bioclick eXoZymes 00:42 <p><p>BioClick: Exponentially increasing the rate of data acquisition by coupling AI with enzyme engineering and high-throughput screening – that unlocks the automated design of novel small molecules.</p><p></p><p>Read more:</p><p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/bioclick">https://exozymes.com/blog/bioclick</a></p></p><p><a href="http://exozymes.twentythree.com/bioclick-an-enzyme-engineering"><img src="http://exozymes.twentythree.com/64968579/111817348/bf0447a271960bbe9b934c5daa4bd1eb/standard/download-18-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/how-exozymes-started-interviews <p><p>Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as Invizyne Technologies in 2019 (rebranded to eXoZymes in 2025), including some of the projects and challenges along the way.</p> </p><p><a href="http://exozymes.twentythree.com/how-exozymes-started-interviews"><img src="http://exozymes.twentythree.com/64968570/110628808/cef80cbbdf8b686eb04f59b8bdd8af3e/standard/download-10-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/110628808 Mon, 10 Mar 2025 20:40:01 GMT How eXoZymes started: Interviews with Tyler Korman and Paul Opgenorth Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as Invizyne Technologies in 2019 (rebranded to eXoZymes in 2025), including some of the projects and challenges along the way. Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as... eXoZymes 06:54 <p><p>Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as Invizyne Technologies in 2019 (rebranded to eXoZymes in 2025), including some of the projects and challenges along the way.</p> </p><p><a href="http://exozymes.twentythree.com/how-exozymes-started-interviews"><img src="http://exozymes.twentythree.com/64968570/110628808/cef80cbbdf8b686eb04f59b8bdd8af3e/standard/download-10-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/the-difference-between-enzymes-and <p><p>What is the difference between enzymes and exozymes? Listen to our CEO, Michael Heltzen, explain it in less than five minutes.</p> <p>#exozymes</p> </p><p><a href="http://exozymes.twentythree.com/the-difference-between-enzymes-and"><img src="http://exozymes.twentythree.com/64968559/109726481/6f5aabb8e097310e6ce588846e2965fc/standard/download-19-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/109726481 Wed, 12 Feb 2025 14:09:16 GMT The difference between enzymes and exozymes: Explaining our tech What is the difference between enzymes and exozymes? Listen to our CEO, Michael Heltzen, explain it in less than five minutes. #exozymes What is the difference between enzymes and exozymes? Listen to our CEO, Michael Heltzen, explain it in less than five minutes. #exozymes eXoZymes 04:52 <p><p>What is the difference between enzymes and exozymes? Listen to our CEO, Michael Heltzen, explain it in less than five minutes.</p> <p>#exozymes</p> </p><p><a href="http://exozymes.twentythree.com/the-difference-between-enzymes-and"><img src="http://exozymes.twentythree.com/64968559/109726481/6f5aabb8e097310e6ce588846e2965fc/standard/download-19-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/creating-value-for-partners-through <p></p><p><a href="http://exozymes.twentythree.com/creating-value-for-partners-through"><img src="http://exozymes.twentythree.com/64968576/109671251/2872f13b5caeb0e1d1b0c98a44137538/standard/download-45-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/109671251 Wed, 12 Feb 2025 14:09:02 GMT Creating value for partners through exozyme biosolutions eXoZymes 08:38 <p></p><p><a href="http://exozymes.twentythree.com/creating-value-for-partners-through"><img src="http://exozymes.twentythree.com/64968576/109671251/2872f13b5caeb0e1d1b0c98a44137538/standard/download-45-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/vision-whats-the-potential-impact <p><p>Listen to our CEO, Michael Heltzen (@heltzen), share his thoughts on how exozymes has the potential to be an even more impactful than transistors.&nbsp; More here:</p> <p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/potential-impact"><a href="https://exozymes.com/blog/potential-impact&nbsp">https://exozymes.com/blog/potential-impact&nbsp</a>;</a>#exozymes $EXOZ</p> </p><p><a href="http://exozymes.twentythree.com/vision-whats-the-potential-impact"><img src="http://exozymes.twentythree.com/64968556/109623760/adf3cab92e41e32a0ac87ce895ae0ca1/standard/download-18-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/109623760 Wed, 12 Feb 2025 14:08:54 GMT Vision: What's the potential impact of exozymes? Listen to our CEO, Michael Heltzen (@heltzen), share his thoughts on how exozymes has the potential to be an even more impactful than transistors. More here: https://exozymes.com/blog/potential-impact#exozymes $EXOZ Listen to our CEO, Michael Heltzen (@heltzen), share his thoughts on how exozymes has the potential to be an even more impactful than transistors. More here: https://exozymes.com/blog/potential-impact#exozymes $EXOZ eXoZymes 03:31 <p><p>Listen to our CEO, Michael Heltzen (@heltzen), share his thoughts on how exozymes has the potential to be an even more impactful than transistors.&nbsp; More here:</p> <p><a target="_blank" rel="noopener noreferrer nofollow" href="https://exozymes.com/blog/potential-impact"><a href="https://exozymes.com/blog/potential-impact&nbsp">https://exozymes.com/blog/potential-impact&nbsp</a>;</a>#exozymes $EXOZ</p> </p><p><a href="http://exozymes.twentythree.com/vision-whats-the-potential-impact"><img src="http://exozymes.twentythree.com/64968556/109623760/adf3cab92e41e32a0ac87ce895ae0ca1/standard/download-18-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/exozymes-signifiy-a-sustainable <p></p><p><a href="http://exozymes.twentythree.com/exozymes-signifiy-a-sustainable"><img src="http://exozymes.twentythree.com/64968569/108824207/9acb19347813bfc6d021617802f31ac8/standard/download-42-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/108824207 Wed, 12 Feb 2025 14:07:54 GMT eXoZymes signifiy a sustainable paradigm shift in chemical production... eXoZymes 03:53 <p></p><p><a href="http://exozymes.twentythree.com/exozymes-signifiy-a-sustainable"><img src="http://exozymes.twentythree.com/64968569/108824207/9acb19347813bfc6d021617802f31ac8/standard/download-42-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/the-story-of-exozymes-interview <p><p>Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as Invizyne Technologies in 2019 (rebranded to eXoZymes in 2025), including some of the projects and challenges along the way.</p></p><p><a href="http://exozymes.twentythree.com/the-story-of-exozymes-interview"><img src="http://exozymes.twentythree.com/64968561/100951904/b84ec0d789f34490d6fac2a00e33164c/standard/download-45-thumbnail.jpg" width="75" height=""/></a></p> http://exozymes.twentythree.com/photo/100951904 Wed, 22 May 2024 16:33:18 GMT The story of eXoZymes: Interview with Tyler Korman and Paul Opgenorth Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as Invizyne Technologies in 2019 (rebranded to eXoZymes in 2025), including some of the projects and challenges along the way. Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as... eXoZymes 06:56 <p><p>Interviews with eXoZymes co-founders, Tyler Korman, PhD - and - Paul Opgenorth, PhD, sharing how the basic idea - liberating the enzymes from the confines of working in cells - was hatched in Jim Bowie's lab at UCLA, before being spun out as Invizyne Technologies in 2019 (rebranded to eXoZymes in 2025), including some of the projects and challenges along the way.</p></p><p><a href="http://exozymes.twentythree.com/the-story-of-exozymes-interview"><img src="http://exozymes.twentythree.com/64968561/100951904/b84ec0d789f34490d6fac2a00e33164c/standard/download-45-thumbnail.jpg" width="75" height=""/></a></p> cannabinoids founder interview invizyne isobutanol jim bowie paul opgenorth SAF sustainable aviation fuel tyler korman